Chemotherapy Instead of Hormone Therapy May Be Preferred For Some Castration-Resistant Prostate Cancer Patients

Chemotherapy Instead of Hormone Therapy May Be Preferred For Some Castration-Resistant Prostate Cancer Patients
Researchers from Johns Hopkins University’s Kimmel Cancer Center and James Buchanan Brady Urological Institute have recently released data showing that men with advanced prostate cancer (PC) and detectable levels of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy equally as men who lack AR-V7.  The study, entitled, “Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer,” was published in the latest edition of JAMA Oncology. Metastatic Castration-Resistant Prostate Cancer Metastatic castration-resistant prostate cancer (MCRPC) occurs when the cancer has spread to other parts of the body, and this growth and spread has continued even after drugs or other treatments to lower the amount of male sex hormones are being administered to manage the disease. Male sex hormones, known as androgens, are often the driving force behind prostate cancer growth, as such, a common treatment option for PC is to lower androgen levels in a man’s body. This can be accomplished by surgically removing the testicles or with drugs that stop the testicles from making andro
Subscribe or to access all post and page content.